Blum A L, Berthet P, Doelle W, Goebell H, Kortüm K, Pelloni S, Peter P, Poulsen H, Strohmeyer G, Tygstrup N
Lancet. 1977 Dec 3;2(8049):1153-5. doi: 10.1016/s0140-6736(77)91540-9.
A double-blind trial of (+)-cyanidanol-3 (2 g/day) versus placebo tablets was carried out in 100 patients with acute viral hepatitis. 51 received the drug and 49 placebo. (+)-Cyanidanol-3 accelerated the disappearance of HBsAg from the blood, lowered serum-bilirubin, and relieved symptoms such as anorexia, nausea, and pruritus. The drug was well tolerated. None of the patients had a relapse of acute hepatitis. Chronic active hepatitis developed in 1 of the placebo-treated patients. Thus, (+)-cyanidanol-3 seems to be of benefit in acute viral hepatitis.
对100例急性病毒性肝炎患者进行了一项双盲试验，比较（+）-氰基丹酚-3（每日2克）与安慰剂片的疗效。51例患者接受药物治疗，49例接受安慰剂治疗。（+）-氰基丹酚-3加速了血液中乙肝表面抗原的消失，降低了血清胆红素，并缓解了厌食、恶心和瘙痒等症状。该药物耐受性良好。所有患者均未出现急性肝炎复发。1例接受安慰剂治疗的患者发展为慢性活动性肝炎。因此，（+）-氰基丹酚-3似乎对急性病毒性肝炎有益。
